Advertisement

Molecular and Cellular Biochemistry

, Volume 335, Issue 1–2, pp 13–17 | Cite as

Association between transforming growth factor β1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects

  • Hai-Ying Xu
  • Xu-Wei Hou
  • Li-Fang Wang
  • Ning-Fu Wang
  • Jian Xu
Article

Abstract

Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbid events in hypertension. TGF-β1 is involved in pathologic states such as cardiac hypertrophy and cardiac fibrosis; we thus postulate that the TGF-β1 polymorphism is related to LVH in hypertensives. Six hundred and eighty essential hypertensive patients were recruited. Biochemical variables and clinical data were obtained and the determination of LVH was performed by echocardiography. According to the presence of LVH, all subjects were divided into the LVH+ and LVH− group. DNA was obtained, and two coding region polymorphisms of the TGF-β1 gene (+869 Leu→Proat codon 10 and +915 ARG→Pro at codon 25) were analyzed by the polymerase chain reaction. The product was cleaved with the restriction endonucleases. For the polymorphisms of the +869 Leu→Pro at codon 10, there was no marked difference in the distributions of genotypes and the allele frequencies between the LVH+ and LVH− subjects. For +915 Arg→Pro at codon 25, a significant difference in the distributions of genotypes of TGF-β1 was observed. The left ventricular mass index (LVMI) in Arg-Pro genotype carriers was significantly higher than those in the Arg-Arg and Pro-Pro carriers. Multivariate analysis showed that the Arg-Pro genotype was an independent risk factor for LVH (OR 3.23, 95% CI [1.48–5.63, P = 0.002]). The codon 10 genotypes did not show a significant association to LVH. Our data revealed a genetic association of TGF-β1+915 Arg→Pro at codon 25 polymorphism with LVH in a Chinese hypertensive population.

Keywords

Transforming growth factor β1 Polymorphism Hypertrophy Essential hypertensive 

Abbreviations

TGF-β1

Transforming growth factor β1

LVH

Left ventricular hypertrophy

LVMI

Left ventricular mass index

Notes

Acknowledgment

This study is supported by a grant from health department of Zhejiang province (2006C068). The authors thank Dr. Han Yunfeng for his help in statistics.

References

  1. 1.
    Koren MJ, Ulin RJ, Koren AT et al (2002) Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 15(12):1021–1028CrossRefPubMedGoogle Scholar
  2. 2.
    Verdecchia P, Schillaci G, Borgioni C et al (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97(1):48–54PubMedGoogle Scholar
  3. 3.
    Verdecchia P, Porcellati C (1993) Defining normal ambulatory blood pressure in relation to target organ damage and prognosis. Am J Hypertens 6:207S–210SPubMedGoogle Scholar
  4. 4.
    Levy D, Garrison RJ, Savage DD et al (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561–1566PubMedGoogle Scholar
  5. 5.
    Meijs MF, de Windt LJ, de Jonge N, Doevendans PA et al (2007) Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 14(2):157–171Google Scholar
  6. 6.
    Schmieder RE (2005) The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 20(12):2610–2612CrossRefPubMedGoogle Scholar
  7. 7.
    Arnett DK, de las Fuentes L, Broeckel U (2004) Genes for left ventricular hypertrophy. Curr Hypertens Rep 6(1):36–41CrossRefPubMedGoogle Scholar
  8. 8.
    Deschepper CF, Boutin-Ganache I, Zahabi A et al (2000) In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 39:332–336CrossRefGoogle Scholar
  9. 9.
    Ignotz RA, Massague J (1986) Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261:4337–4345PubMedGoogle Scholar
  10. 10.
    He ZY, Feng B, Yang SL et al (2005) Intracardiac basic fibroblast growth factor and transforming growth factor-beta 1 mRNA and their proteins expression level in patients with pressure or volume-overload right or left ventricular hypertrophy. Acta Cardiol 60:21–25CrossRefPubMedGoogle Scholar
  11. 11.
    Agrotis A, Kalinina N, Bobik A (2005) Transforming growth factor-beta, cell signaling and cardiovascular disorders. Curr Vasc Pharmacol 3:55–61CrossRefPubMedGoogle Scholar
  12. 12.
    Andreotti F, Porto I, Crea F, Maseri A (2002) Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 87:107–112CrossRefPubMedGoogle Scholar
  13. 13.
    Nikol S, Isner JM, Pickering JG et al (1992) Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest 90:1582–1592CrossRefPubMedGoogle Scholar
  14. 14.
    Lijnen PJ, Petrov VV, Fagard RH (2000) Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 71(1–2):418–435CrossRefPubMedGoogle Scholar
  15. 15.
    Sie MP, Mattace-Raso FU, Uitterlinden AG et al (2007) TGF-beta1 polymorphisms and arterial stiffness; the Rotterdam Study. J Hum Hypertens 21(6):431–437PubMedGoogle Scholar
  16. 16.
    Crobu F, Palumbo L, Franco E, et al (2008) Role of TGF-beta1 haplotypes in the occurrence of myocardial infarction in young Italian patients. BMC Med Genet 9:13Google Scholar
  17. 17.
    Sie MP, Uitterlinden AG, Bos MJ et al (2006) TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke 37(11):2667–2671CrossRefPubMedGoogle Scholar
  18. 18.
    Koch W, Hoppmann P, Mueller JC et al (2006) Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler Thromb Vasc Biol 26(5):1114–1119CrossRefPubMedGoogle Scholar
  19. 19.
    Cambien F, Ricard S, Troesch A et al (1996) Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l’Infarctus du Myocarde (ECTIM) Study. Hypertension 28(5):881–887PubMedGoogle Scholar
  20. 20.
    Xue H, Wang S, Wang H et al (2008) Atrial natriuretic peptide gene promoter polymorphism is associated with left ventricular hypertrophy in hypertension. Clin Sci 114(2):131–137CrossRefPubMedGoogle Scholar
  21. 21.
    Rao M, Guo D, Jaber BL et al (2004) Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int 66(1):419–427CrossRefPubMedGoogle Scholar
  22. 22.
    Holweg CT, Baan CC, Niesters HG et al (2001) TGF-beta1 gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant 20(9):979–984CrossRefPubMedGoogle Scholar
  23. 23.
    Holweg CT, Baan CC, Balk AH et al (2001) The transforming growth factor-beta1 codon 10 gene polymorphism and accelerated graft vascular disease after clinical heart transplantation. Transplantation 71(10):1463–1467Google Scholar
  24. 24.
    Yokota M, Ichihara S, Lin TL et al (2000) Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101(24):2783–2787PubMedGoogle Scholar
  25. 25.
    Hallberg P, Karlsson J, Lind L et al (2004) Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment—results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clin Cardiol 27(5):287–290CrossRefPubMedGoogle Scholar
  26. 26.
    Aziz TM, Hasleton PS, Yona N et al (2001) Transforming growth factor beta: association with arteriosclerosis and left ventricular dysfunction after heart transplantation. Transplant Proc 33:2334–2336CrossRefPubMedGoogle Scholar
  27. 27.
    Awad MR, El-gamel A, Hasleton P et al (1998) Genotypic variation in the transforming growth factor-beta1 gene: Association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66:1014–1020CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Hai-Ying Xu
    • 1
  • Xu-Wei Hou
    • 1
  • Li-Fang Wang
    • 2
  • Ning-Fu Wang
    • 1
  • Jian Xu
    • 1
  1. 1.Department of Cardiology, Hangzhou First Municipal Hospital and Hangzhou HospitalNanjing Medical UniversityHangzhouChina
  2. 2.Department of Basic MedicineZhejiang Medical CollegeHangzhouChina

Personalised recommendations